AlzGene - Gene overview of all published AD-association studies for MAPT/STH
Back Search Methods Disclaimer Credits
 Gene: MAPT/STH  (TAU; MTBT2; FTDP-17; FLJ31424; MSTD; PPND; DDPAC; MAPTL; MTBT1; STH/MAPT)  Entrez Gene    View on ALSGene   View on MSGene   View on PDGene   View on SZGene
 Protein: microtubule-associated protein tau/saitohin  (microtubule-associated protein tau; saitohin)  ProteinLink
 Chromosome: 17   (View: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  X  Y  MT)
 Status: Updated 18 April 2011 ;  Because of the complete correlation between genetic markers in MAPT and STH, these two loci have been combined for display in this database
Meta-Analysis
1. Case-Control Studies (by ethnic group)
      AD Cases Normal Controls    
Study Population Source # Polys # Subjects
(% women)
DX Onset Age
(range)
Age
(range)
# Subjects
(% women)
Age
(range)
Result Comment
 Caucasian
Abraham, 2009
UK CL  6  (detail)  1082
(71%)
C75.8 + 6.7
(60-95)
-1239
(62%)
76.5 + 6.3
(-)
Trend
Baker, 2000
Finland PO  1  (detail)  110
(-)
M--174
(-)
-Negative
Bullido, 2000
Spain CL  1  (detail)  167
(-)
M69.1 + 5.1
(53-79)
-194
(-)
68.2 + 7.4
(-)
Positive
Clark, 2003
USA CL  1  (detail)  15
(-)
C--129
(-)
-Negative
Combarros, 2003
Spain CL  1  (detail)  315
(70%)
C71.9 + 8.8
(48-95)
75.6 + 9
(50-98)
307
(72%)
80.5 + 7.7
(63-100)
Positive
Conrad, 1997
Unknown    1  (detail)  173
(-)
U--61
(-)
-Negative
Conrad, 2004
Germany CL  1  (detail)  155
(-)
N-80.9 + 6.9
(-)
41
(-)
76.1 + 5.6
(-)
Negative
Cook, 2002
UK CL  1  (detail)  203
(66%)
N-81.4 + 7.8
(-)
309
(59%)
82.1 + 3.8
(-)
Negative
Cousin, 2009
France CL  7  (detail)  428
(-)
C64.9 + 9.9
(-)
-475
(-)
66.2 + 10.8
(-)
Trend
Ezquerra, 1999
Spain    1  (detail)  74
(51%)
C65.2 + 10.5
(-)
-195
(51%)
61.4 + 13.9
(-)
Negative
Feulner, 2009
Germany CL  20  (detail)  491
(57%)
C-72.2
(-)
479
(46%)
39.5
(-)
Positive
Garcia, 2009
Overlaps with
Combarros, 2003
CL  1  (detail)  285
(63%)
C-75.9 + 8.7
(50-97)
382
(67%)
81 + 7.7
(51-100)
n.a.
Giedraitis, 2009
Sweden (ULSAM) CL  1  (detail)  86
(0%)
C80.2
(72-85)
-404
(0%)
81.8
(80-84)
Negative
Johansson, 2005
Sweden    1  (detail)  398
(58%)
M73 + 7.7
(-)
77 + 7.1
(-)
186
(56%)
72 + 9.2
(-)
Negative 
Kaivorinne, 2008
Finland CL  1  (detail)  122
(55%)
C-58.2
(38-64)
198
(-)
40.6
(19-64)
Positive
Kauwe, 2008
USA CL  1  (detail)  361
(-)
C--358
(-)
-Positive
Kwok, 2008
UK CO  3  (detail)  604
(68%)
C-82 + 6.4
(-)
589
(69%)
77 + 6.5
(-)
Positive
Kwok, 2008
Australia PO  3  (detail)  129
(-)
C--171
(-)
-Positive
Kwon, 2000
USA CL  1  (detail)  266
(50%)
C70 + 9.1
(-)
-278
(59%)
74.5 + 9
(-)
Negative
Laws, 2006
Germany CL  6  (detail)  433
(59%)
C69.3 + 9.4
(-)
72.4 + 9.5
(-)
279
(57%)
67.2 + 11.6
(-)
Positive
Li, 2008
Canada CL  4  (detail)  753
(58%)
C71.9 + 8.5
(-)
77.8 + 8.6
(-)
736
(64%)
73.4 + 7.9
(-)
Trend
Lilius, 1999
Sweden (I) CL  7  (detail)  136
(-)
M65 + 9
(-)
-62
(-)
73 + 12
(-)
Negative
Lilius, 1999
Sweden (II) PO  7  (detail)  94
(-)
C80 + 5
(-)
-176
(-)
88 + 4
(-)
Negative
Mateo, 2006
Overlaps with
Combarros, 2003
CL  1  (detail)  333
(67%)
C72.1 + 8.6
(48-95)
75.7 + 9
(50-98)
307
(70%)
80.4 + 7.8
(63-100)
n.a.
Mateo, 2008
Spain CL  1  (detail)  293
(65%)
C72.1 + 8.2
(48-93)
-396
(67%)
81 + 7.6
(51-100)
Negative
Mukherjee, 2007
USA (WashU) CL  6  (detail)  361
(-)
C--358
(-)
-Negative
Myers, 2005
USA    6  (detail)  181
(55%)
N-81
(66-97)
131
(51%)
81
(65-99)
Positive
Myers, 2005
UK    6  (detail)  179
(66%)
N-81
(65-96)
121
(51%)
78
(65-100)
Positive
Myers, 2006
Overlaps with
Schjeide, 2009
CL  6  (detail)  296
(55%)
N-83
(65-102)
128
(44%)
80
(65-102)
Positive
Oliveria, 2003
USA CL  1  (detail)  903
(67%)
M--320
(54%)
-Negative
Peplonska, 2003
Poland CL  1  (detail)  100
(64%)
C71.5 + 4.2
(-)
76.4 + 4.1
(-)
100
(79%)
71.2 + 5.9
(-)
Negative
Randall, 2009
USA CL  1  (detail)  181
(71%)
C--119
(52%)
-Positive
Reiman, 2007
USA, Netherlands CL  3  (detail)  861
(-)
M-74.9 + 6.6
(-)
550
(-)
77.4 + 7.3
(-)
Negative
Roks, 1999
Netherlands PO  2  (detail)  101
(-)
C57 + 5
(-)
63 + 4.9
(-)
117
(-)
61 + 3.3
(-)
Negative
Russ, 2001
UK CO  1  (detail)  200
(76%)
C77.5 + 7.3
(-)
-189
(-)
80.1 + 4
(-)
Negative
Seripa, 2004
USA CL  1  (detail)  117
(55%)
N71.6 + 8.8
(-)
80.9 + 7.9
(-)
99
(54%)
83.7 + 8.2
(-)
Negative
Seripa, 2004
Italy CL  1  (detail)  130
(58%)
C65.9 + 7.2
(-)
69.8 + 7.3
(-)
105
(46%)
62.4 + 10.5
(-)
Negative
Streffer, 2003
Switzerland CL  1  (detail)  91
(-)
C--92
(-)
-Negative
Streffer, 2003
Greece CL  1  (detail)  134
(-)
C--52
(-)
-Negative
Vazquez-Higuera, 2009
Overlaps with
Mateo, 2008
CL  1  (detail)  246
(65%)
C72.9 + 7.1
(60-93)
76.6 + 7.3
(62-97)
237
(69%)
81.2 + 7.7
(63-100)
n.a.
Verpillat, 2002
Overlaps with
Cousin, 2009
CL  1  (detail)  499
(62%)
-63.8 + 9.7
(41-90)
-402
(52%)
66.6 + 10.2
(-)
n.a.
Webster, 2010
Overlaps with
Reiman, 2007
CL  1  (detail)  861
(-)
M-82.8 + 7.7
(-)
550
(-)
79.7 + 6.3
(-)
Negative 
Zuo, 2006
USA CL  1  (detail)  369
(61%)
C69.3 + 8.3
(45-87)
73.6 + 8.4
(52-93)
289
(55%)
40.8 + 8.3
(18-88)
Negative
 African Descent
Clark, 2003
USA CL  1  (detail)  65
(-)
C--118
(-)
-Negative
 Asian
Kwok, 2008
China CL  3  (detail)  179
(93%)
C-84.3 + 6.2
(-)
188
(73%)
73.8 + 7.1
(-)
Positive
Lin, 2008
China CL  1  (detail)  280
(75%)
C75.8 + 9.7
(-)
79.7 + 9.3
(-)
220
(72%)
78.5 + 8.9
(-)
Negative
Sun, 2008
China CL  1  (detail)  252
(54%)
C60.5 + 5.8
(-)
68.3 + 7.3
(-)
197
(53%)
69.2 + 8
(-)
Positive
Tanahashi, 2004
Japan CL  2  (detail)  874
(65%)
C70 + 8.8
(42-91)
-678
(60%)
67 + 10.1
(33-91)
Positive
Wang, 2008
China CL  1  (detail)  207
(52%)
C-77.6 + 6.4
(65-97)
222
(39%)
72.3 + 5.3
(65-77)
n.a.
 Hispanic
Clark, 2003
USA CL  1  (detail)  120
(-)
C--211
(-)
-Negative
Forero, 2005
Colombia CL  1  (detail)  106
(71%)
C68.8 + 8.7
(-)
73.3 + 8.8
(-)
97
(-)
72.2 + 8.7
(-)
Negative
 Other/Mixed
Baker, 2000
USA    1  (detail)  546
(-)
M--419
(-)
-Negative
Conrad, 2002
USA CL  1  (detail)  51
(-)
N-80.5
(56-98)
30
(-)
78.8
(55-97)
Positive
Crawford, 1999
USA CL,CO  2  (detail)  265
(47%)
C-73.2 + 6.3
(-)
142
(60%)
75.2 + 7.3
(-)
Negative
Contact us if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.
2. Family-Based Studies (by ethnic group)
      Affecteds Unaffecteds    
Study Population # Polys # Families # Subjects
(% women)
DX Onset Age
(range)
Age
(range)
# Subjects
(% women)
Age
(range)
Result Comment
 Other/Mixed
Oliveria, 2003
USA  1  (detail)  6901499
(-)
M--320
(-)
-Negative
Schjeide, 2009
USA (CAG)  1  (detail)  217222
(59%)
M69.2 + 9
(50-89)
-267
(63%)
72.9 + 8.8
(49-92)
Positive
Schjeide, 2009
USA (NCRAD)  1  (detail)  340741
(74%)
M71.3 + 7.6
(50-98)
-300
(55%)
71 + 8.4
(39-93)
Negative
Schjeide, 2009
USA (NIA)  1  (detail)  351803
(64%)
M74.1 + 7.1
(52-98)
-290
(59%)
73.3 + 9.5
(36-94)
Negative
Schjeide, 2009
Overlaps with
Oliveria, 2003
 1  (detail)  436995
(74%)
M72.4 + 7.7
(50-97)
-411
(58%)
70 + 10.7
(31-93)
n.a.
Contact us if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.
Source:  Source of case population -> “CL” (clinic-based), “PO” (population-based), or “CO” (community-based).
# Polys:  Number of polymorphisms tested per gene and per sample.
Onset Age and Age:  Mean or median age at onset or examination, respectively.
DX:  Criteria used to determine AD diagnosis ->  "C" (clinical AD diagnosis), "N" (neuropathological AD diagnosis), "M" (mixed, i.e. AD sample contains both clinical and neuropathological cases), "U" (unknown).
Result:  Overall conclusion reached by authors of the original publication (“positive” usually indicates significant (P<0.05) association in at least one of the performed analyses, and “negative” indicates no evidence for significant association, while “trend” indicates results in between); results obtained in duplicate or largely overlapping samples are listed as "n.a.".
(-) :  Either no data provided or in case of overlap, data included in original study.
AlzGene Recent Updates
AlzGene Top Results
AlzGene Stats
Studies: 1395
Genes: 695
Polymorphisms: 2973
Meta-analyses: 320
Cure Alzheimer's Fund
Proud supporter of the AlzGene database.
Michael J. Fox Foundation
The PDGene database is supported by a grant from The Michael J. Fox Foundation in partnership with the Alzheimer Research Forum.

NCRAD

The National Cell Repository for Alzheimer Disease seeks to recruit 1,000 families with two or more living brothers or sisters who have been diagnosed with late onset Alzheimer’s disease.
ALSGene
AlzGene
MSGene
PDGene
SZGene
An up-to-date collection of all published genetic association studies.